Histone Variants Group

Publications

Prostate cancer epigenetic biomarkers: next-generation technologies
Valdes-Mora, F.
; Clark, S. J.;
ONCOGENE 34(13):1609-1618, 2015
Clinical relevance of the transcriptional signature regulated by CDC42 in colorectal cancer
Valdes-Mora, F.; Locke, W. J.; Bandres, E.; Gallego-Ortega, D.; Cejas, P.; Garcia-Cabezas, M. A.; Colino-Sanguino, Y.; Feliu, J.; Del Pulgar, T. G.; Lacal, J. C.
Oncotarget 8(16):26755-26770, 2017
Acetylated histone variant H2A.Z is involved in the activation of neo-enhancers in prostate cancer
Valdes-Mora, F.; Gould, C. M.; Colino-Sanguino, Y.; Qu, W.; Song, J. Z.; Taylor, K. M.; Buske, F. A.; Statham, A. L.; Nair, S. S.; Armstrong, N. J.; Kench, J. G.; Lee, K. M. L.; Horvath, L. G.; Qiu, M.; Ilinykh, A.; Yeo-Teh, N. S.; Gallego-Ortega, D.; Stirzaker, C.; Clark, S. J.
Nature Communications 8(1):1346, 2017
Acetylation of H2A.Z is a key epigenetic modification associated with gene deregulation and epigenetic remodeling in cancer
Valdes-Mora, F.; Song, J.Z.; Statham, A.L.; Strbenac, D.; Robinson, M.D.; Nair, S.S.; Patterson, K.I.; Tremethick, D.J.; Stirzaker, C.; Clark, S.J.
GENOME RESEARCH 22(2):307-21, 2012